Rady Childrens Hospital - San Diego
- Type
- Teaching hospital
- Where
- San Diego, CA
- Medicare CCN
- 053303
- Received
- $1,014,982 in 263 records, 2023 ($670,175 general, $344,806 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: RADY CHILDRENS HOSPITAL SAN DIEGO Fuzzy (name and state)
- Nonprofit: RADY CHILDRENS HOSPITAL SAN DIEGO Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 35 | $670,175 |
| 2023 | Research payment | 228 | $344,806 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | 2 | $510,000 | 2023 |
| ABBVIE INC. | 15 | $109,664 | 2023 |
| Horizon Therapeutics plc | 1 | $100,000 | 2023 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $58,525 | 2023 |
| Siemens Medical Solutions USA, Inc. | 2 | $50,540 | 2023 |
| KLS-Martin L.P. | 5 | $50,000 | 2023 |
| Novo Nordisk AS | 199 | $32,959 | 2023 |
| Medtronic, Inc. | 4 | $28,814 | 2023 |
| National Marrow Donor Program | 4 | $12,035 | 2023 |
| Travere Therapeutics, Inc. | 1 | $10,000 | 2023 |
| MED-EL Corporation | 1 | $7,950 | 2023 |
| PFIZER INC. | 3 | $6,739 | 2023 |
| Novo Nordisk Inc | 1 | $6,413 | 2023 |
| Abbott Laboratories | 3 | $6,000 | 2023 |
| JAZZ PHARMACEUTICALS INC. | 1 | $5,000 | 2023 |
| Neurelis, Inc. | 1 | $5,000 | 2023 |
| Stryker Corporation | 7 | $4,169 | 2023 |
| KARL STORZ Endoscopy-America | 1 | $3,000 | 2023 |
| Electromed, Inc. | 1 | $2,000 | 2023 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $2,000 | 2023 |
| Novartis Pharmaceuticals Corporation | 2 | $1,906 | 2023 |
| Incyte Corporation | 1 | $1,000 | 2023 |
| Xeris Pharmaceuticals, Inc. | 1 | $500 | 2023 |
| Becton, Dickinson and Company | 2 | $402 | 2023 |
| Amgen Inc. | 1 | $242 | 2023 |
| Medline Industries LP | 1 | $100 | 2023 |
| B. Braun Medical Inc. | 1 | $18 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $507,035 |
| Research payment | 228 | $344,806 |
| Grant | 7 | $103,000 |
| Space rental or facility fees (teaching hospital only) | 6 | $27,500 |
| Charitable Contribution | 2 | $12,500 |
| Long term medical supply or device loan | 5 | $11,894 |
| Education | 5 | $5,920 |
| Food and Beverage | 1 | $2,000 |
| Debt forgiveness | 4 | $325 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Medtronic, Inc. | $2,994 | Research payment | In-kind items and services | CIP336 Fiasp | 2023 | |
| 2023-12-31 | Stryker Corporation | $2,164 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Medtronic, Inc. | $1,690 | Research payment | In-kind items and services | CIP335 Lyumjev | 2023 | |
| 2023-12-31 | Stryker Corporation | $1,474 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $540 | Research payment | In-kind items and services | Rady2023MRIPR085073039Hegde | 2023 | |
| 2023-12-31 | Stryker Corporation | $152 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $152 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $125 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Medline Industries LP | $100 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Stryker Corporation | $60 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Stryker Corporation | $40 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-04 | ABBVIE INC. | $20,353 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-11-30 | Abbott Laboratories | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2023-11-30 | Xeris Pharmaceuticals, Inc. | $500 | Education | Cash or cash equivalent | GVOKE HYPOPEN Drug, Diabetes | 2023 | |
| 2023-10-25 | KLS-Martin L.P. | $10,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-10-20 | National Marrow Donor Program | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-27 | ABBVIE INC. | $20,353 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-09-21 | ABBVIE INC. | $2,035 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-09-15 | Novo Nordisk AS | $28,828 | Research payment | Cash or cash equivalent | NN7415-4616 | 2023 | |
| 2023-09-15 | Novo Nordisk AS | $3,250 | Research payment | Cash or cash equivalent | NN7415-4616 | 2023 | |
| 2023-09-12 | JAZZ PHARMACEUTICALS INC. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | 2023 | |
| 2023-09-11 | ABBVIE INC. | $10,176 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-09-11 | ABBVIE INC. | $2,544 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-09-11 | ABBVIE INC. | $2,035 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-09-08 | Novo Nordisk AS | $75 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-08-28 | Novartis Pharmaceuticals Corporation | $1,538 | Research payment | In-kind items and services | KYMRIAH Drug, Oncology | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2023 |
| 2023-08-22 | Horizon Therapeutics plc | $100,000 | Research payment | Cash or cash equivalent | RAVICTI Drug, RAVICTI | NBS-BY-WGS, A LEARNING SYSTEM FOR NBS FOR GENETIC DISEASE BY RAPID WHOLE GENOME SEQUENCING (RWGS) | 2023 |
| 2023-08-17 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | 2023 | |
| 2023-08-10 | Neurelis, Inc. | $5,000 | Education | Cash or cash equivalent | VALTOCO Drug, EPILEPSY | 2023 | |
| 2023-08-04 | National Marrow Donor Program | $4,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-08-02 | KLS-Martin L.P. | $10,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-08-02 | B. Braun Medical Inc. | $18 | Education | In-kind items and services | 2023 | ||
| 2023-07-31 | Electromed, Inc. | $2,000 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2023 | |
| 2023-07-25 | ABBVIE INC. | $30,534 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-07-25 | ABBVIE INC. | $203 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Enhancement of venetoclax in acute myeloid leukemia | 2023 |
| 2023-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $58,525 | Research payment | Cash or cash equivalent | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2023 |
| 2023-06-30 | Medtronic, Inc. | $21,163 | Research payment | In-kind items and services | CIP335 Lyumjev | 2023 | |
| 2023-06-30 | Medtronic, Inc. | $2,966 | Research payment | In-kind items and services | CIP336 Fiasp | 2023 | |
| 2023-06-29 | PFIZER INC. | $3,329 | Research payment | In-kind items and services | AZTREONAMAVIBACTAM PEDIATRIC TRIAL | 2023 | |
| 2023-06-27 | Travere Therapeutics, Inc. | $10,000 | Charitable Contribution | Cash or cash equivalent | 2023 | ||
| 2023-06-23 | Novo Nordisk Inc | $6,413 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2023 |
| 2023-06-20 | VERTEX PHARMACEUTICALS INCORPORATED | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TRIKAFTA Drug, CYSTIC FIBROSIS | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 | |
| 2023-06-15 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | NN7415-4616 | 2023 |
The latest 200 records of 263.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Diego, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Diego, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 1,389,526 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 1,386,932 | 3,298,634 | 39,538,223 |
| Median age B01002 | 36.2 | 37.3 | 37.9 |
| Under 18 B01001 | 18.4% | 20.9% | 22.0% |
| 65 and over B01001 | 14.6% | 15.4% | 15.7% |
| Households B11001 | 530,412 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 25.1% | 22.8% | 27.0% |
| Median household income B19013 | $108,077 | $106,268 | $99,122 |
| Median family income B19113 | $128,006 | $122,377 | $113,346 |
| Per capita income B19301 | $57,083 | $51,976 | $49,513 |
| Poverty rate B17001 | 11.0% | 10.3% | 12.0% |
| Unemployment rate B23025 | 6.0% | 6.1% | 6.6% |
| Civilian labor force B23025 | 755,893 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 23.5 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 51.0% | 43.2% | 37.1% |
| Housing units B25001 | 568,668 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 47.3% | 54.6% | 55.9% |
| Renters B25003 | 52.7% | 45.4% | 44.1% |
| Median home value B25077 | $906,700 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,313 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 40.9% | 42.4% | 33.8% |
| Black B03002 | 5.3% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 29.8% | 34.6% | 40.2% |
| Asian B03002 | 17.3% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Diego, CA.
Comments